CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Income Statement [Abstract] | ||||||||
| Product Revenues – net of Discounts and Rebates | $ 207,898 | $ 100,932 | $ 369,990 | $ 264,484 | ||||
| Cost of Revenues | 151,100 | 50,051 | 236,815 | 123,323 | ||||
| Gross Profit | 56,798 | 50,881 | 133,175 | 141,161 | ||||
| Research Revenues | 206,939 | 299,670 | ||||||
| Net Revenue | 56,798 | 257,820 | 133,175 | 440,831 | ||||
| Operating Expenses: | ||||||||
| Research and Development | 598,653 | 231,912 | 880,117 | 602,725 | ||||
| General and Administrative Expenses | 1,729,247 | 1,632,236 | 3,619,121 | 3,355,372 | ||||
| Total Operating Expenses | 2,327,900 | 1,864,148 | 4,499,238 | 3,958,097 | ||||
| Loss from Operations | (2,271,102) | (1,606,328) | (4,366,063) | (3,517,266) | ||||
| Interest Expense | (1,403) | (1,221) | (2,792) | (3,011) | ||||
| Change in Fair Value of Derivative Liabilities | (5,665) | (140,447) | (10,232) | (135,342) | ||||
| Other Income, net | 12,584 | 13,066 | 23,346 | 43,388 | ||||
| Total Interest and Other Income (Loss), net | 5,516 | (128,602) | 10,322 | (94,965) | ||||
| Loss from Operations before Provision for Income Taxes | (2,265,586) | (1,734,930) | (4,355,741) | (3,612,231) | ||||
| Provision for Income Taxes (Note 10) | ||||||||
| Net Loss including Noncontrolling Interest | (2,265,586) | (1,734,930) | (4,355,741) | (3,612,231) | ||||
| Net Loss – Noncontrolling Interest | (1,060) | (1,204) | (2,001) | (1,956) | ||||
| Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | (2,264,526) | (1,733,726) | (4,353,740) | (3,610,275) | ||||
| Comprehensive Loss: | ||||||||
| Net Loss | (2,265,586) | (1,734,930) | (4,355,741) | (3,612,231) | ||||
| Unrealized Foreign Currency Translation Gain | 2,552 | 17,242 | 8,494 | 7,338 | ||||
| Total Comprehensive Loss | (2,263,034) | (1,717,688) | (4,347,247) | (3,604,893) | ||||
| Net Loss – Noncontrolling Interest | (1,060) | (1,204) | (2,001) | (1,956) | ||||
| Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | (2,261,974) | (1,716,484) | (4,345,246) | (3,602,937) | ||||
| Cumulative Dividends on Series A Preferred Stock | (134,307) | (126,705) | (259,619) | (244,863) | ||||
| Net Loss - attributed to common stockholders | $ (2,396,281) | $ (1,843,189) | $ (4,604,865) | $ (3,847,800) | ||||
| Net Loss per Common Share: | ||||||||
| Basic (in Dollars per share) | [1] | $ (0.9) | $ (5.01) | $ (2.1) | $ (11.16) | |||
| Diluted (in Dollars per share) | $ (0.9) | [1] | $ (5.01) | [1] | $ (2.1) | $ (11.16) | ||
| Weighted Average Number of Common Shares Outstanding | ||||||||
| Basic (in Shares) | [1] | 2,653,848 | 368,250 | 2,192,367 | 344,701 | |||
| Diluted (in Shares) | 2,653,848 | [1] | 368,250 | [1] | 2,192,367 | 344,701 | ||
| ||||||||
| X | ||||||||||
- Definition The amount of net revenue loss. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after tax, of unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders. Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue that is not accounted for under Topic 606, classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|